Patents by Inventor Jonathan S. Wall
Jonathan S. Wall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240003912Abstract: Provided herein are methods of detecting and diagnosing types of amyloid-related diseases. Also provided herein are methods of treatment comprising selecting a treatment based upon a particular type of amyloid disease.Type: ApplicationFiled: December 3, 2021Publication date: January 4, 2024Inventors: Jonathan S. WALL, Robert Eric HEIDEL
-
Publication number: 20230416347Abstract: Provided herein are antibody-peptide fusion proteins comprising an amyloid-reactive peptide linked to an antibody. Also provided herein are methods of treating amyloid-based diseases by administering an antibody-peptide fusion protein.Type: ApplicationFiled: April 11, 2023Publication date: December 28, 2023Inventors: Jonathan S. WALL, James S. FOSTER, Spencer GUTHRIE, Jaume PONS, Michael L. KLEIN
-
Publication number: 20230265178Abstract: Provided herein are modified immunoglobulins comprising an amyloid reactive peptide joined to an antibody, as well as humanized antibodies that bind to human amyloid fibrils and antibody-peptide fusion proteins. Also provided herein are methods of treating amyloid-based diseases by administering a modified immunoglobulin, humanized antibody, or antibody-peptide fusion protein.Type: ApplicationFiled: March 9, 2023Publication date: August 24, 2023Inventors: Jonathan S. WALL, James S. FOSTER, Spencer GUTHRIE
-
Publication number: 20230068507Abstract: Provided herein are chimeric receptors comprising amyloid binding regions, as well as cells comprising the chimeric receptors. Also provided herein are methods of treating amyloid-based diseases by administering a cell comprising a chimeric receptor.Type: ApplicationFiled: January 15, 2021Publication date: March 2, 2023Inventor: Jonathan S. WALL
-
Publication number: 20220411489Abstract: Provided herein are modified immunoglobulins comprising an amyloid reactive peptide joined to an antibody, as well as humanized antibodies that bind to human amyloid fibrils and antibody-peptide fusion proteins. Also provided herein are methods of treating amyloid-based diseases by administering a modified immunoglobulin, humanized antibody, or antibody-peptide fusion protein.Type: ApplicationFiled: November 13, 2020Publication date: December 29, 2022Inventors: Jonathan S. WALL, James S. FOSTER, Spencer GUTHRIE
-
Patent number: 11293925Abstract: Immunoglobulin light chain proteins are used to generate synthetic fibrils in vitro. The fibrils are mixed with immunoglobulin light chain proteins from a biological sample. In either a direct binding assay, competition assay, or dilution-based competition assay, a signal is detected from the mixture. The intensity of the detectable signal relates to the level of binding between the immunoglobulin light chain proteins to the fibrils and can thus be used to identify amyloidogenic immunoglobulin light chain proteins in a biological sample of the subject and to assess amyloidogenic risk to a subject. For example, the signal intensities from the assays can be used in a comparison to one or more threshold (control) values derived from samples of known light chain types or in the absence of light chains. The comparisons permit identification of amyloidogenic proteins, assessment of amyloidogenic risk, and categorization of the subject into an appropriate “at risk” group.Type: GrantFiled: October 19, 2018Date of Patent: April 5, 2022Inventors: Jonathan S. Wall, Emily Martin
-
Patent number: 10646568Abstract: Disclosed are methods and compositions for targeting antibodies to amyloid deposits. For example, amyloid-reactive peptides that bind amyloid deposits are administered to a subject. Antibodies to the amyloid-reactive peptides are then administered to the subject. Upon administration of the antibodies, the amyloid-reactive peptides bind the antibodies and thus pre-target the antibodies to the amyloid deposits. In other examples, an amyloid-reactive fusion peptide contains an epitope of a known antibody. When the fusion peptide is administered to a subject, the fusion peptide binds amyloids in the subject. Administration to the subject of the known antibody that binds the epitope of the fusion peptide then targets the antibody to the amyloid deposit to which the fusion peptide is bound.Type: GrantFiled: July 16, 2018Date of Patent: May 12, 2020Assignee: UNIVERSITY OF TENESSEE RESEARCH FOUNDATIONInventors: Jonathan S Wall, Stephen J Kennel, James S Foster
-
Patent number: 10308685Abstract: Disclosed are methods of treating and/or inhibiting a viral infection in a subject. The methods include administering a therapeutically effective amount of heparin-binding peptide. Also disclosed herein are methods for blocking viral binding to a cell. Further disclosed are anti-viral compositions for administration to a subject infected with a virus. Administration of the anti-viral composition inhibits viral infection of the subject.Type: GrantFiled: May 25, 2017Date of Patent: June 4, 2019Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Jonathan S. Wall, Timothy E. Sparer, Stephen J. Kennel
-
Publication number: 20190083616Abstract: Disclosed are methods and compositions for targeting antibodies to amyloid deposits. For example, amyloid-reactive peptides that bind amyloid deposits are administered to a subject. Antibodies to the amyloid-reactive peptides are then administered to the subject. Upon administration of the antibodies, the amyloid-reactive peptides bind the antibodies and thus pre-target the antibodies to the amyloid deposits. In other examples, an amyloid-reactive fusion peptide contains an epitope of a known antibody. When the fusion peptide is administered to a subject, the fusion peptide binds amyloids in the subject. Administration to the subject of the known antibody that binds the epitope of the fusion peptide then targets the antibody to the amyloid deposit to which the fusion peptide is bound.Type: ApplicationFiled: July 16, 2018Publication date: March 21, 2019Inventors: Jonathan S. Wall, Stephen J. Kennel, James S. Foster
-
Patent number: 10213506Abstract: Disclosed are methods and compositions for targeting antibodies to amyloid deposits. For example, amyloid-reactive peptides that bind amyloid deposits are administered to a subject. Antibodies to the amyloid-reactive peptides are then administered to the subject. Upon administration of the antibodies, the amyloid-reactive peptides bind the antibodies and thus pre-target the antibodies to the amyloid deposits. In other examples, an amyloid-reactive fusion peptide contains an epitope of a known antibody. When the fusion peptide is administered to a subject, the fusion peptide binds amyloids in the subject. Administration to the subject of the known antibody that binds the epitope of the fusion peptide then targets the antibody to the amyloid deposit to which the fusion peptide is bound.Type: GrantFiled: August 24, 2015Date of Patent: February 26, 2019Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Jonathan S. Wall, Stephen J. Kennel, James S. Foster
-
Publication number: 20190041390Abstract: Immunoglobulin light chain proteins are used to generate synthetic fibrils in vitro. The fibrils are mixed with immunoglobulin light chain proteins from a biological sample. In either a direct binding assay, competition assay, or dilution-based competition assay, a signal is detected from the mixture. The intensity of the detectable signal relates to the level of binding between the immunoglobulin light chain proteins to the fibrils and can thus be used to identify amyloidogenic immunoglobulin light chain proteins in a biological sample of the subject and to assess amyloidogenic risk to a subject. For example, the signal intensities from the assays can be used in a comparison to one or more threshold (control) values derived from samples of known light chain types or in the absence of light chains. The comparisons permit identification of amyloidogenic proteins, assessment of amyloidogenic risk, and categorization of the subject into an appropriate “at risk” group.Type: ApplicationFiled: October 19, 2018Publication date: February 7, 2019Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Jonathan S. WALL, Emily MARTIN
-
Patent number: 10046050Abstract: Disclosed are methods and compositions for targeting antibodies to amyloid deposits. For example, amyloid-reactive peptides that bind amyloid deposits are administered to a subject. Antibodies to the amyloid-reactive peptides are then administered to the subject. Upon administration of the antibodies, the amyloid-reactive peptides bind the antibodies and thus pre-target the antibodies to the amyloid deposits. In other examples, an amyloid-reactive fusion peptide contains an epitope of a known antibody. When the fusion peptide is administered to a subject, the fusion peptide binds amyloids in the subject. Administration to the subject of the known antibody that binds the epitope of the fusion peptide then targets the antibody to the amyloid deposit to which the fusion peptide is bound.Type: GrantFiled: February 24, 2016Date of Patent: August 14, 2018Assignee: UNIVERSITY OF TENESSEE RESEARCH FOUNDATIONInventors: Jonathan S. Wall, Stephen J. Kennel, James S. Foster
-
Publication number: 20170281807Abstract: Disclosed are methods and compositions for targeting antibodies to amyloid deposits. For example, amyloid-reactive peptides that bind amyloid deposits are administered to a subject. Antibodies to the amyloid-reactive peptides are then administered to the subject. Upon administration of the antibodies, the amyloid-reactive peptides bind the antibodies and thus pre-target the antibodies to the amyloid deposits. In other examples, an amyloid-reactive fusion peptide contains an epitope of a known antibody. When the fusion peptide is administered to a subject, the fusion peptide binds amyloids in the subject. Administration to the subject of the known antibody that binds the epitope of the fusion peptide then targets the antibody to the amyloid deposit to which the fusion peptide is bound.Type: ApplicationFiled: August 24, 2015Publication date: October 5, 2017Inventors: Jonathan S. WALL, Stephen J. KENNEL, James S. FOSTER
-
Publication number: 20170267722Abstract: Disclosed are methods of treating and/or inhibiting a viral infection in a subject. The methods include administering a therapeutically effective amount of heparin-binding peptide. Also disclosed herein are methods for blocking viral binding to a cell. Further disclosed are anti-viral compositions for administration to a subject infected with a virus. Administration of the anti-viral composition inhibits viral infection of the subject.Type: ApplicationFiled: May 25, 2017Publication date: September 21, 2017Inventors: Jonathan S. Wall, Timothy E. Sparer, Stephen J. Kennel
-
Patent number: 9683017Abstract: Disclosed are methods of treating and/or inhibiting a viral infection in a subject. The methods include administering a therapeutically effective amount of heparin-binding peptide. Also disclosed herein are methods for blocking viral binding to a cell. Further disclosed are anti-viral compositions for administration to a subject infected with a virus. Administration of the anti-viral composition inhibits viral infection of the subject.Type: GrantFiled: July 16, 2015Date of Patent: June 20, 2017Assignee: UNIVERSITY TENNESSEE RESEARCH FOUNDATIONInventors: Jonathan S. Wall, Timothy E. Sparer, Stephen J. Kennel
-
Publication number: 20160243230Abstract: Disclosed are methods and compositions for targeting antibodies to amyloid deposits. For example, amyloid-reactive peptides that bind amyloid deposits are administered to a subject. Antibodies to the amyloid-reactive peptides are then administered to the subject. Upon administration of the antibodies, the amyloid-reactive peptides bind the antibodies and thus pre-target the antibodies to the amyloid deposits. In other examples, an amyloid-reactive fusion peptide contains an epitope of a known antibody. When the fusion peptide is administered to a subject, the fusion peptide binds amyloids in the subject. Administration to the subject of the known antibody that binds the epitope of the fusion peptide then targets the antibody to the amyloid deposit to which the fusion peptide is bound.Type: ApplicationFiled: February 24, 2016Publication date: August 25, 2016Inventors: Jonathan S. WALL, Stephen J. KENNEL, James S. FOSTER
-
Publication number: 20160016999Abstract: Disclosed are methods of treating and/or inhibiting a viral infection in a subject. The methods include administering a therapeutically effective amount of heparin-binding peptide. Also disclosed herein are methods for blocking viral binding to a cell. Further disclosed are anti-viral compositions for administration to a subject infected with a virus. Administration of the anti-viral composition inhibits viral infection of the subject.Type: ApplicationFiled: July 16, 2015Publication date: January 21, 2016Inventors: Jonathan S. Wall, Timothy E. Sparer, Stephen J. Kennel
-
Publication number: 20090246191Abstract: The present invention provides a method of purifying cross-linked oligomers. The purified cross-linked oligomers are useful as immunogen for generating and isolating cross-linked oligomer reactive antibodies. The cross-linked oligomer reactive antibodies are useful for detecting amyloid deposition and for diagnosing and treating diseases and conditions associated with amyloid deposition.Type: ApplicationFiled: October 14, 2008Publication date: October 1, 2009Applicant: University of Tennessee Research FoundationInventors: Brian O'Nuallain, Alan Solomon, Jonathan S. Wall, Luis Acero, Angela Williams
-
Publication number: 20090232733Abstract: The present invention provides IGIV and IGIV enriched for binding to amyloid fibrils and to partially denatured amyloidogenic precursor polypeptides. The present invention also provides methods for obtaining IGIV enriched for binding to amyloid fibrils and to partially denatured amyloidogenic precursor polypeptides. The IGIV recognizes amyloid fibrils and partially denatured amyloidogenic precursor polypeptides. They are useful for treating diseases and conditions associated with amyloid deposition. The IGIV of the present invention also are useful for diagnosing and detecting amyloid deposition.Type: ApplicationFiled: April 13, 2006Publication date: September 17, 2009Inventors: Brian O'Nuallain, Rudi Hrncic, Jonathan S. Wall, Alan Solomon
-
Patent number: RE47838Abstract: Disclosed are methods of treating and/or inhibiting a viral infection in a subject. The methods include administering a therapeutically effective amount of heparin-binding peptide. Also disclosed herein are methods for blocking viral binding to a cell. Further disclosed are anti-viral compositions for administration to a subject infected with a virus. Administration of the anti-viral composition inhibits viral infection of the subject.Type: GrantFiled: January 30, 2018Date of Patent: February 4, 2020Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Jonathan S. Wall, Timothy E. Sparer, Stephen J. Kennel